Llwytho...
Tracking down response and resistance to TRK inhibitors
Two recent studies validate the LMNA-NTRK1 fusion as an oncogenic driver and therapeutic target of TRK inhibitors. The LMNA-NTRK1 fusion occurs at low frequency across multiple tumor types. The studies highlight the increasing need to develop molecular biomarker-based clinical trials across cancer s...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cancer Discov |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4709026/ https://ncbi.nlm.nih.gov/pubmed/26747892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-1352 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|